Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector
Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial primary microRNAs (apri-miRs) has shown promise in...
Saved in:
| Published in | Virology journal Vol. 22; no. 1; p. 41 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
17.02.2025
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1743-422X 1743-422X |
| DOI | 10.1186/s12985-025-02662-5 |
Cover
| Abstract | Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial primary microRNAs (apri-miRs) has shown promise in preclinical studies. A recently designed synthetic ancestral AAV (Anc80L65) with high liver transduction efficiency is a promising new addition to the anti-HBV vector toolbox. This study engineered Anc80L65 to express
HBx
-targeting apri-miRs. Single dose administration of the vectors to cultured cells and HBV transgenic mice effected reductions of secreted HBV surface antigen (HBsAg). Circulating HBV particles and HBV core antigen (HBcAg) were also significantly diminished in mice receiving the anti-HBV apri-miR-expressing ancestral AAVs. Downregulation of HBV biomarkers occurred over a period of 12 months. Absence of inflammatory responses or liver toxicity indicated that the vectors had a good safety profile. These data suggest that a single dose of apri-miR-expressing Anc80L65 is safe and capable of mediating durable suppression of HBV gene expression. Targeting
HBx
, which is required for transcriptional activity of covalently closed circular DNA of HBV, makes this Anc80L65-derived vector a promising candidate for functional cure from chronic HBV infection. |
|---|---|
| AbstractList | Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial primary microRNAs (apri-miRs) has shown promise in preclinical studies. A recently designed synthetic ancestral AAV (Anc80L65) with high liver transduction efficiency is a promising new addition to the anti-HBV vector toolbox. This study engineered Anc80L65 to express HBx-targeting apri-miRs. Single dose administration of the vectors to cultured cells and HBV transgenic mice effected reductions of secreted HBV surface antigen (HBsAg). Circulating HBV particles and HBV core antigen (HBcAg) were also significantly diminished in mice receiving the anti-HBV apri-miR-expressing ancestral AAVs. Downregulation of HBV biomarkers occurred over a period of 12 months. Absence of inflammatory responses or liver toxicity indicated that the vectors had a good safety profile. These data suggest that a single dose of apri-miR-expressing Anc80L65 is safe and capable of mediating durable suppression of HBV gene expression. Targeting HBx, which is required for transcriptional activity of covalently closed circular DNA of HBV, makes this Anc80L65-derived vector a promising candidate for functional cure from chronic HBV infection. Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial primary microRNAs (apri-miRs) has shown promise in preclinical studies. A recently designed synthetic ancestral AAV (Anc80L65) with high liver transduction efficiency is a promising new addition to the anti-HBV vector toolbox. This study engineered Anc80L65 to express HBx -targeting apri-miRs. Single dose administration of the vectors to cultured cells and HBV transgenic mice effected reductions of secreted HBV surface antigen (HBsAg). Circulating HBV particles and HBV core antigen (HBcAg) were also significantly diminished in mice receiving the anti-HBV apri-miR-expressing ancestral AAVs. Downregulation of HBV biomarkers occurred over a period of 12 months. Absence of inflammatory responses or liver toxicity indicated that the vectors had a good safety profile. These data suggest that a single dose of apri-miR-expressing Anc80L65 is safe and capable of mediating durable suppression of HBV gene expression. Targeting HBx , which is required for transcriptional activity of covalently closed circular DNA of HBV, makes this Anc80L65-derived vector a promising candidate for functional cure from chronic HBV infection. Abstract Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial primary microRNAs (apri-miRs) has shown promise in preclinical studies. A recently designed synthetic ancestral AAV (Anc80L65) with high liver transduction efficiency is a promising new addition to the anti-HBV vector toolbox. This study engineered Anc80L65 to express HBx-targeting apri-miRs. Single dose administration of the vectors to cultured cells and HBV transgenic mice effected reductions of secreted HBV surface antigen (HBsAg). Circulating HBV particles and HBV core antigen (HBcAg) were also significantly diminished in mice receiving the anti-HBV apri-miR-expressing ancestral AAVs. Downregulation of HBV biomarkers occurred over a period of 12 months. Absence of inflammatory responses or liver toxicity indicated that the vectors had a good safety profile. These data suggest that a single dose of apri-miR-expressing Anc80L65 is safe and capable of mediating durable suppression of HBV gene expression. Targeting HBx, which is required for transcriptional activity of covalently closed circular DNA of HBV, makes this Anc80L65-derived vector a promising candidate for functional cure from chronic HBV infection. Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial primary microRNAs (apri-miRs) has shown promise in preclinical studies. A recently designed synthetic ancestral AAV (Anc80L65) with high liver transduction efficiency is a promising new addition to the anti-HBV vector toolbox. This study engineered Anc80L65 to express HBx-targeting apri-miRs. Single dose administration of the vectors to cultured cells and HBV transgenic mice effected reductions of secreted HBV surface antigen (HBsAg). Circulating HBV particles and HBV core antigen (HBcAg) were also significantly diminished in mice receiving the anti-HBV apri-miR-expressing ancestral AAVs. Downregulation of HBV biomarkers occurred over a period of 12 months. Absence of inflammatory responses or liver toxicity indicated that the vectors had a good safety profile. These data suggest that a single dose of apri-miR-expressing Anc80L65 is safe and capable of mediating durable suppression of HBV gene expression. Targeting HBx, which is required for transcriptional activity of covalently closed circular DNA of HBV, makes this Anc80L65-derived vector a promising candidate for functional cure from chronic HBV infection.Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial primary microRNAs (apri-miRs) has shown promise in preclinical studies. A recently designed synthetic ancestral AAV (Anc80L65) with high liver transduction efficiency is a promising new addition to the anti-HBV vector toolbox. This study engineered Anc80L65 to express HBx-targeting apri-miRs. Single dose administration of the vectors to cultured cells and HBV transgenic mice effected reductions of secreted HBV surface antigen (HBsAg). Circulating HBV particles and HBV core antigen (HBcAg) were also significantly diminished in mice receiving the anti-HBV apri-miR-expressing ancestral AAVs. Downregulation of HBV biomarkers occurred over a period of 12 months. Absence of inflammatory responses or liver toxicity indicated that the vectors had a good safety profile. These data suggest that a single dose of apri-miR-expressing Anc80L65 is safe and capable of mediating durable suppression of HBV gene expression. Targeting HBx, which is required for transcriptional activity of covalently closed circular DNA of HBV, makes this Anc80L65-derived vector a promising candidate for functional cure from chronic HBV infection. Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial primary microRNAs (apri-miRs) has shown promise in preclinical studies. A recently designed synthetic ancestral AAV (Anc80L65) with high liver transduction efficiency is a promising new addition to the anti-HBV vector toolbox. This study engineered Anc80L65 to express HBx-targeting apri-miRs. Single dose administration of the vectors to cultured cells and HBV transgenic mice effected reductions of secreted HBV surface antigen (HBsAg). Circulating HBV particles and HBV core antigen (HBcAg) were also significantly diminished in mice receiving the anti-HBV apri-miR-expressing ancestral AAVs. Downregulation of HBV biomarkers occurred over a period of 12 months. Absence of inflammatory responses or liver toxicity indicated that the vectors had a good safety profile. These data suggest that a single dose of apri-miR-expressing Anc80L65 is safe and capable of mediating durable suppression of HBV gene expression. Targeting HBx, which is required for transcriptional activity of covalently closed circular DNA of HBV, makes this Anc80L65-derived vector a promising candidate for functional cure from chronic HBV infection. Keywords: AAV, Ancestral AAV, Hepatitis B virus, Microrna |
| ArticleNumber | 41 |
| Audience | Academic |
| Author | Ely, Abdullah Mnyandu, Njabulo Ziphezinhle Wadee, Reubina Limani, Shonisani Wendy Arbuthnot, Patrick Maepa, Mohube Betty |
| Author_xml | – sequence: 1 givenname: Njabulo Ziphezinhle surname: Mnyandu fullname: Mnyandu, Njabulo Ziphezinhle organization: Wits/SAMRC Antiviral Gene Therapy Research Unit, Infectious Diseases and Oncology Research Institute (IDORI), Faculty of Health Sciences, University of the Witwatersrand – sequence: 2 givenname: Shonisani Wendy surname: Limani fullname: Limani, Shonisani Wendy organization: Wits/SAMRC Antiviral Gene Therapy Research Unit, Infectious Diseases and Oncology Research Institute (IDORI), Faculty of Health Sciences, University of the Witwatersrand – sequence: 3 givenname: Abdullah surname: Ely fullname: Ely, Abdullah organization: Wits/SAMRC Antiviral Gene Therapy Research Unit, Infectious Diseases and Oncology Research Institute (IDORI), Faculty of Health Sciences, University of the Witwatersrand – sequence: 4 givenname: Reubina surname: Wadee fullname: Wadee, Reubina organization: Department of Anatomical Pathology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Services – sequence: 5 givenname: Patrick surname: Arbuthnot fullname: Arbuthnot, Patrick organization: Wits/SAMRC Antiviral Gene Therapy Research Unit, Infectious Diseases and Oncology Research Institute (IDORI), Faculty of Health Sciences, University of the Witwatersrand – sequence: 6 givenname: Mohube Betty surname: Maepa fullname: Maepa, Mohube Betty email: Betty.Maepa@wits.ac.za organization: Wits/SAMRC Antiviral Gene Therapy Research Unit, Infectious Diseases and Oncology Research Institute (IDORI), Faculty of Health Sciences, University of the Witwatersrand |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39962472$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk12L1DAUhousuB_6B7yQgDfuRdckTZP2StZF3YEBwQ_wLqTJaTdDJxmTdti99Zdvuh2HHRCVEpqcPOcl583JaXbkvIMse0nwBSEVfxsJrasyx3QanNO8fJKdEMGKnFH64-jR_Dg7jXGFcUG5qJ9lx0Vdc8oEPcl-Lb3r8gHCGll3Yxs7WO-Qb9E1bNSQVhG9R1sbxog6cIDgdhMgxglq7pBCm2DXKtyhtdXBB6f2gOuQchriEFSPlAHncxWj11YNYCbFFN6CHnx4nj1tVR_hxe5_ln3_-OHb1XW-_PxpcXW5zHXJyZDTtqVlyzRAJQrCm0aUlDRcAGOGKc0rjWtVKQ5EGWxaTTAnBgwVpFbaMFacZYtZ13i1kruDS6-sfAj40EkVBqt7kNgITripymQeI0Y1aa6AVYxUomkKkbTezVqbsVmD0eCmOg9ED3ecvZGd38p0cQWjZZ0U3uwUgv85Jp_k2kYNfa8c-DHKgmJOCcP8v9DUA2VZ8H-jhFeJxWQq4fWMdipVbF3r00H1hMvLiopK8JpOghd_oNJnIF156sfWpvhBwvlBQmIGuB06NcYoF1-_HLKvHru4t-93eyaAzkBqrhgDtHuE4MlKLuc3IFNN8uENyDIlFXNSTLDrIMiVH1Nr9vFvWfcEaglL |
| Cites_doi | 10.1016/j.antiviral.2017.07.006 10.1172/JCI79213 10.1016/S0166-3542(01)00178-4 10.1007/978-1-4939-3112-5_20 10.1016/j.gtc.2019.02.005 10.1038/s41587-020-0741-7 10.1136/gutjnl-2020-323445 10.1016/j.omtn.2017.04.007 10.15252/emmm.201506172 10.1038/mt.2008.231 10.1056/NEJMoa1407309 10.1136/gutjnl-2024-333026 10.1038/s41573-019-0012-9 10.1038/mt.2008.144 10.1080/17843286.2022.2152566 10.1111/j.1365-2567.2008.02986.x 10.1128/JVI.73.1.161-169.1999 10.1002/hep.21364 10.1073/pnas.0807027105 10.1172/JCI43565 10.1089/hum.2018.015 10.1038/sj.mt.6300077 10.1038/nature17170 10.1089/hum.2019.264 10.3851/IMP2713 10.1007/978-1-0716-0290-4_10 10.1128/JVI.76.12.6356-6363.2002 10.1093/cid/ciy1100 10.1128/JVI.80.1.426-439.2006 10.1038/nbt.3440 10.1128/jvi.69.10.6158-6169.1995 10.1038/s41392-024-01871-8 10.1186/1743-422X-10-74 10.1038/nature04791 10.1016/j.antiviral.2021.105140 10.1038/gt.2014.94 10.1016/j.jconrel.2015.04.042 10.1038/sj.gt.3301514 10.1615/CritRevImmunol.v32.i1.30 10.3389/fmicb.2023.1322892 10.1016/j.ymthe.2017.09.021 10.3390/v16091361 10.1089/hum.2018.007 10.1016/j.celrep.2015.07.019 10.1093/nar/gkp446 10.2174/1568010043483908 10.1038/ng.3893 10.1056/NEJMoa1708483 10.1128/JVI.73.11.9468-9477.1999 10.1038/ng.3389 10.1038/nmeth.2089 10.1172/jci.insight.131610 10.3390/biom13081208 10.3390/v12080851 10.1016/j.jhep.2021.08.010 10.1155/2014/718743 10.1038/mt.2008.82 10.1371/journal.pone.0130052 10.3390/v13112247 10.1038/317489a0 10.1016/j.bmc.2011.12.024 10.1073/pnas.1704766114 10.1016/j.bbrc.2013.12.052 10.1128/jvi.66.7.4107-4116.1992 10.1111/jcmm.13444 10.1021/mp800157x 10.1002/hep.26990 10.1016/j.aohep.2024.101533 10.1128/JVI.75.1.311-322.2001 10.1128/JVI.72.11.8568-8577.1998 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 7X8 7S9 L.6 5PM DOA |
| DOI | 10.1186/s12985-025-02662-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic AGRICOLA AGRICOLA MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals (ODIN) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1743-422X |
| EndPage | 41 |
| ExternalDocumentID | oai_doaj_org_article_0d7616d8542241dab6d8ae484187bb37 PMC11834259 A827876926 39962472 10_1186_s12985_025_02662_5 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GeographicLocations | South Africa |
| GeographicLocations_xml | – name: South Africa |
| GrantInformation_xml | – fundername: Council for Scientific and Industrial Research – fundername: South African National Research Foundation grantid: 118022 and 120383 – fundername: South African Medical Research Council funderid: http://dx.doi.org/10.13039/501100001322 – fundername: Carnegie/WITS University Enabling grant – fundername: Female Academic Leadership Fund |
| GroupedDBID | --- 0R~ 123 29Q 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAHBH AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IGS IHR INH INR ISR ITC KQ8 LGEZI LOTEE M1P M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM PMFND 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c561t-2ff25f4cee87316bb7521b67e44d4ac68c09a8a6e1ad0dfc1061ded2719acd443 |
| IEDL.DBID | C6C |
| ISSN | 1743-422X |
| IngestDate | Wed Aug 27 01:22:35 EDT 2025 Thu Aug 21 18:28:44 EDT 2025 Fri Sep 05 16:18:52 EDT 2025 Fri Sep 05 17:26:36 EDT 2025 Thu Sep 04 18:25:51 EDT 2025 Tue Jun 17 21:59:19 EDT 2025 Tue Jun 10 20:59:19 EDT 2025 Fri Jun 27 05:15:44 EDT 2025 Sun Aug 03 01:53:02 EDT 2025 Wed Sep 10 04:38:49 EDT 2025 Sat Sep 06 07:30:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Microrna Ancestral AAV Hepatitis B virus AAV |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c561t-2ff25f4cee87316bb7521b67e44d4ac68c09a8a6e1ad0dfc1061ded2719acd443 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doi.org/10.1186/s12985-025-02662-5 |
| PMID | 39962472 |
| PQID | 3168025017 |
| PQPubID | 24069 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0d7616d8542241dab6d8ae484187bb37 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11834259 proquest_miscellaneous_3206214069 proquest_miscellaneous_3200255536 proquest_miscellaneous_3168025017 gale_infotracmisc_A827876926 gale_infotracacademiconefile_A827876926 gale_incontextgauss_ISR_A827876926 pubmed_primary_39962472 crossref_primary_10_1186_s12985_025_02662_5 springer_journals_10_1186_s12985_025_02662_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-02-17 |
| PublicationDateYYYYMMDD | 2025-02-17 |
| PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Virology journal |
| PublicationTitleAbbrev | Virol J |
| PublicationTitleAlternate | Virol J |
| PublicationYear | 2025 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | AB van Nunen (2662_CR9) 2001; 52 R Loomba (2662_CR39) 2019; 69 J Lucifora (2662_CR71) 2017; 145 D Ivacik (2662_CR43) 2015; 22 M Iwamoto (2662_CR31) 2014; 443 M Huang (2662_CR41) 2018; 22 2662_CR47 T Bourhill (2662_CR25) 2015 JC Nault (2662_CR44) 2015; 47 P Tiollais (2662_CR6) 1985; 317 D Duan (2662_CR48) 1999; 73 D Duan (2662_CR49) 1998; 72 Y Yanagawa (2662_CR58) 2009; 127 LV Tse (2662_CR66) 2017; 114 SS Iyer (2662_CR56) 2012; 32 J Yang (2662_CR50) 1999; 73 KI Berns (2662_CR75) 2019; 48 Y Davidov (2662_CR10) 2023; 78 T Michler (2662_CR23) 2016; 8 2662_CR13 D Grimm (2662_CR30) 2006; 80 2662_CR19 2662_CR17 2662_CR18 J Brzezinska (2662_CR15) 2012; 20 A Ely (2662_CR32) 2009; 37 M Nassal (2662_CR26) 1992; 66 WR Addison (2662_CR4) 2002; 76 A Westhaus (2662_CR37) 2020; 31 Y Zhu (2662_CR3) 2001; 75 E Zinn (2662_CR24) 2015; 12 MB Mowa (2662_CR38) 2014; 2014 RJ Chandler (2662_CR45) 2015; 125 D Wang (2662_CR51) 2019; 18 M Hosel (2662_CR67) 2014; 59 2662_CR69 D Grimm (2662_CR61) 2010; 120 DM McCarty (2662_CR29) 2001; 8 C Crowther (2662_CR33) 2016; 1364 CA Schneider (2662_CR35) 2012; 9 S Carmona (2662_CR14) 2009; 6 K Sekiba (2662_CR12) 2022; 76 A Decorsiere (2662_CR7) 2016; 531 2662_CR62 LG Guidotti (2662_CR68) 1995; 69 S Rangarajan (2662_CR21) 2017; 377 JM Murray (2662_CR40) 2006; 44 AC Nathwani (2662_CR52) 2014; 371 U Kassner (2662_CR20) 2018; 29 F Wang (2662_CR11) 2023; 14 K Pekrun (2662_CR65) 2019; 4 MB Maepa (2662_CR22) 2017; 7 C Crowther (2662_CR55) 2014; 19 (2662_CR34) 2003 JC Giering (2662_CR59) 2008; 16 BE Deverman (2662_CR63) 2016; 34 BL Ellis (2662_CR36) 2013; 10 K Hanazaki (2662_CR8) 2004; 3 2662_CR73 N Mnyandu (2662_CR28) 2020; 2115 W Zai (2662_CR74) 2024; 9 D Grimm (2662_CR60) 2006; 441 2662_CR72 A Ely (2662_CR42) 2008; 16 MS Weinberg (2662_CR27) 2007; 15 GJ Logan (2662_CR46) 2017; 49 NK Paulk (2662_CR64) 2018; 26 GN Nguyen (2662_CR53) 2021; 39 2662_CR2 C Hinderer (2662_CR54) 2018; 29 MD Marimani (2662_CR16) 2015; 209 M Hacham (2662_CR57) 2004; 15 2662_CR70 2662_CR1 PG Naully (2662_CR5) 2024; 30 |
| References_xml | – volume: 145 start-page: 14 year: 2017 ident: 2662_CR71 publication-title: Antiviral Res doi: 10.1016/j.antiviral.2017.07.006 – volume: 125 start-page: 870 issue: 2 year: 2015 ident: 2662_CR45 publication-title: J Clin Investig doi: 10.1172/JCI79213 – volume: 52 start-page: 139 issue: 2 year: 2001 ident: 2662_CR9 publication-title: Antiviral Res doi: 10.1016/S0166-3542(01)00178-4 – volume: 1364 start-page: 249 year: 2016 ident: 2662_CR33 publication-title: Methods Mol Biol doi: 10.1007/978-1-4939-3112-5_20 – volume: 48 start-page: 319 issue: 2 year: 2019 ident: 2662_CR75 publication-title: Gastroenterol Clin North Am doi: 10.1016/j.gtc.2019.02.005 – volume-title: Successful disabling of the 5’ UTR of HCV using adeno-associated viral vectors to deliver artificial primary microrna mimics year: 2015 ident: 2662_CR25 – volume: 39 start-page: 47 issue: 1 year: 2021 ident: 2662_CR53 publication-title: Nat Biotechnol doi: 10.1038/s41587-020-0741-7 – ident: 2662_CR17 doi: 10.1136/gutjnl-2020-323445 – volume: 7 start-page: 190 year: 2017 ident: 2662_CR22 publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2017.04.007 – volume: 8 start-page: 1082 issue: 9 year: 2016 ident: 2662_CR23 publication-title: EMBO Mol Med doi: 10.15252/emmm.201506172 – ident: 2662_CR62 doi: 10.1038/mt.2008.231 – volume: 371 start-page: 1994 issue: 21 year: 2014 ident: 2662_CR52 publication-title: N Engl J Med doi: 10.1056/NEJMoa1407309 – ident: 2662_CR18 doi: 10.1136/gutjnl-2024-333026 – volume: 18 start-page: 358 issue: 5 year: 2019 ident: 2662_CR51 publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-019-0012-9 – volume: 16 start-page: 1630 issue: 9 year: 2008 ident: 2662_CR59 publication-title: Mol Ther doi: 10.1038/mt.2008.144 – volume: 78 start-page: 291 issue: 4 year: 2023 ident: 2662_CR10 publication-title: Acta Clin Belg doi: 10.1080/17843286.2022.2152566 – volume: 127 start-page: 345 issue: 3 year: 2009 ident: 2662_CR58 publication-title: Immunology doi: 10.1111/j.1365-2567.2008.02986.x – volume: 73 start-page: 161 issue: 1 year: 1999 ident: 2662_CR48 publication-title: J Virol doi: 10.1128/JVI.73.1.161-169.1999 – volume: 44 start-page: 1117 issue: 5 year: 2006 ident: 2662_CR40 publication-title: Hepatology doi: 10.1002/hep.21364 – ident: 2662_CR19 doi: 10.1073/pnas.0807027105 – volume: 120 start-page: 3106 issue: 9 year: 2010 ident: 2662_CR61 publication-title: J Clin Invest doi: 10.1172/JCI43565 – volume: 29 start-page: 285 issue: 3 year: 2018 ident: 2662_CR54 publication-title: Hum Gene Ther doi: 10.1089/hum.2018.015 – volume: 15 start-page: 534 issue: 3 year: 2007 ident: 2662_CR27 publication-title: Mol Ther doi: 10.1038/sj.mt.6300077 – volume: 531 start-page: 386 issue: 7594 year: 2016 ident: 2662_CR7 publication-title: Nature doi: 10.1038/nature17170 – ident: 2662_CR47 – volume: 31 start-page: 575 issue: 9–10 year: 2020 ident: 2662_CR37 publication-title: Hum Gene Ther doi: 10.1089/hum.2019.264 – volume: 19 start-page: 363 issue: 4 year: 2014 ident: 2662_CR55 publication-title: Antivir Ther doi: 10.3851/IMP2713 – volume: 2115 start-page: 171 year: 2020 ident: 2662_CR28 publication-title: Methods Mol Biol doi: 10.1007/978-1-0716-0290-4_10 – volume: 76 start-page: 6356 issue: 12 year: 2002 ident: 2662_CR4 publication-title: J Virol doi: 10.1128/JVI.76.12.6356-6363.2002 – volume: 69 start-page: 542 issue: 3 year: 2019 ident: 2662_CR39 publication-title: Clin Infect Dis doi: 10.1093/cid/ciy1100 – volume: 80 start-page: 426 issue: 1 year: 2006 ident: 2662_CR30 publication-title: J Virol doi: 10.1128/JVI.80.1.426-439.2006 – volume: 34 start-page: 204 issue: 2 year: 2016 ident: 2662_CR63 publication-title: Nat Biotechnol doi: 10.1038/nbt.3440 – volume: 69 start-page: 6158 issue: 10 year: 1995 ident: 2662_CR68 publication-title: J Virol doi: 10.1128/jvi.69.10.6158-6169.1995 – volume: 9 start-page: 150 issue: 1 year: 2024 ident: 2662_CR74 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-024-01871-8 – volume: 10 start-page: 74 year: 2013 ident: 2662_CR36 publication-title: Virol J doi: 10.1186/1743-422X-10-74 – volume: 441 start-page: 537 issue: 7092 year: 2006 ident: 2662_CR60 publication-title: Nature doi: 10.1038/nature04791 – ident: 2662_CR69 doi: 10.1016/j.antiviral.2021.105140 – start-page: 197 volume-title: A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus. Frontieviral Viral Hepatitis year: 2003 ident: 2662_CR34 – ident: 2662_CR1 – volume: 22 start-page: 163 issue: 2 year: 2015 ident: 2662_CR43 publication-title: Gene Ther doi: 10.1038/gt.2014.94 – volume: 209 start-page: 198 year: 2015 ident: 2662_CR16 publication-title: J Control Release doi: 10.1016/j.jconrel.2015.04.042 – volume: 8 start-page: 1248 issue: 16 year: 2001 ident: 2662_CR29 publication-title: Gene Ther doi: 10.1038/sj.gt.3301514 – volume: 32 start-page: 23 issue: 1 year: 2012 ident: 2662_CR56 publication-title: Crit Rev Immunol doi: 10.1615/CritRevImmunol.v32.i1.30 – volume: 14 start-page: 1322892 year: 2023 ident: 2662_CR11 publication-title: Front Microbiol doi: 10.3389/fmicb.2023.1322892 – volume: 26 start-page: 289 issue: 1 year: 2018 ident: 2662_CR64 publication-title: Mol Ther doi: 10.1016/j.ymthe.2017.09.021 – ident: 2662_CR13 doi: 10.3390/v16091361 – volume: 29 start-page: 520 issue: 4 year: 2018 ident: 2662_CR20 publication-title: Hum Gene Ther doi: 10.1089/hum.2018.007 – volume: 12 start-page: 1056 issue: 6 year: 2015 ident: 2662_CR24 publication-title: Cell Rep doi: 10.1016/j.celrep.2015.07.019 – volume: 37 start-page: e91 issue: 13 year: 2009 ident: 2662_CR32 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkp446 – volume: 3 start-page: 63 issue: 1 year: 2004 ident: 2662_CR8 publication-title: Curr Drug Targets Inflamm Allergy doi: 10.2174/1568010043483908 – volume: 49 start-page: 1267 issue: 8 year: 2017 ident: 2662_CR46 publication-title: Nat Genet doi: 10.1038/ng.3893 – volume: 377 start-page: 2519 issue: 26 year: 2017 ident: 2662_CR21 publication-title: N Engl J Med doi: 10.1056/NEJMoa1708483 – volume: 73 start-page: 9468 issue: 11 year: 1999 ident: 2662_CR50 publication-title: J Virol doi: 10.1128/JVI.73.11.9468-9477.1999 – volume: 47 start-page: 1187 issue: 10 year: 2015 ident: 2662_CR44 publication-title: Nat Genet doi: 10.1038/ng.3389 – volume: 9 start-page: 671 issue: 7 year: 2012 ident: 2662_CR35 publication-title: Nat Methods doi: 10.1038/nmeth.2089 – volume: 4 start-page: e131610 issue: 22 year: 2019 ident: 2662_CR65 publication-title: JCI Insight doi: 10.1172/jci.insight.131610 – ident: 2662_CR2 doi: 10.3390/biom13081208 – ident: 2662_CR73 doi: 10.3390/v12080851 – volume: 76 start-page: 53 issue: 1 year: 2022 ident: 2662_CR12 publication-title: J Hepatol doi: 10.1016/j.jhep.2021.08.010 – volume: 2014 start-page: p718743 year: 2014 ident: 2662_CR38 publication-title: Biomed Res Int doi: 10.1155/2014/718743 – volume: 16 start-page: 1105 issue: 6 year: 2008 ident: 2662_CR42 publication-title: Mol Ther doi: 10.1038/mt.2008.82 – ident: 2662_CR72 doi: 10.1371/journal.pone.0130052 – ident: 2662_CR70 doi: 10.3390/v13112247 – volume: 317 start-page: 489 issue: 6037 year: 1985 ident: 2662_CR6 publication-title: Nature doi: 10.1038/317489a0 – volume: 20 start-page: 1594 issue: 4 year: 2012 ident: 2662_CR15 publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2011.12.024 – volume: 114 start-page: E4812 issue: 24 year: 2017 ident: 2662_CR66 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1704766114 – volume: 15 start-page: 37 issue: 1 year: 2004 ident: 2662_CR57 publication-title: Eur Cytokine Netw – volume: 443 start-page: 808 issue: 3 year: 2014 ident: 2662_CR31 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2013.12.052 – volume: 66 start-page: 4107 issue: 7 year: 1992 ident: 2662_CR26 publication-title: J Virol doi: 10.1128/jvi.66.7.4107-4116.1992 – volume: 22 start-page: 1675 issue: 3 year: 2018 ident: 2662_CR41 publication-title: J Cell Mol Med doi: 10.1111/jcmm.13444 – volume: 6 start-page: 706 issue: 3 year: 2009 ident: 2662_CR14 publication-title: Mol Pharm doi: 10.1021/mp800157x – volume: 59 start-page: 2110 issue: 6 year: 2014 ident: 2662_CR67 publication-title: Hepatology doi: 10.1002/hep.26990 – volume: 30 start-page: 101533 issue: 1 year: 2024 ident: 2662_CR5 publication-title: Ann Hepatol doi: 10.1016/j.aohep.2024.101533 – volume: 75 start-page: 311 issue: 1 year: 2001 ident: 2662_CR3 publication-title: J Virol doi: 10.1128/JVI.75.1.311-322.2001 – volume: 72 start-page: 8568 issue: 11 year: 1998 ident: 2662_CR49 publication-title: J Virol doi: 10.1128/JVI.72.11.8568-8577.1998 |
| SSID | ssj0032679 |
| Score | 2.4082422 |
| SecondaryResourceType | review_article |
| Snippet | Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8... Abstract Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 41 |
| SubjectTerms | AAV Ancestral AAV Animals Anopheles Antigens biomarkers Biomedical and Life Sciences Biomedicine chemical bonding Circular DNA Dependovirus - genetics Gene expression Gene Expression Regulation, Viral Genes Genetic aspects Genetic engineering Genetic Therapy - methods Genetic transcription Genetic Vectors genetically modified organisms Health aspects Hepatitis B Hepatitis B Core Antigens - blood Hepatitis B Surface Antigens - blood Hepatitis B virus Hepatitis B virus - genetics Hepatitis B virus - physiology Hepatitis B, Chronic - therapy Hepatitis B, Chronic - virology hepatotoxicity Humans Infection Liver Mice Mice, Transgenic MicroRNA MicroRNAs - genetics MicroRNAs - metabolism Research Article Review serotypes surface antigens Trans-Activators - genetics transcription (genetics) Viral Regulatory and Accessory Proteins Virology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJRAXBOUVKMggJA4Q1XEcxzm2iGpBlANQqTfLju1tDk1Qs1vRK7-cGSdZNUVaLhwireKRk3g-z2M9D0LeSGYk6F2XimDLVHhXp1VQRVq5IjDvAUQKk5OPv8rFifh8Wpxea_WFMWFDeeBh4faZA0dbOlUIVDbOWPhtvFAiU6W1ecwjZxWbnKlBBoNNUlZTioyS-z1oNYWZyHhJCe7XTA3Fav1_y-RrSulmwOSNU9OojI7uk3ujFUkPhrd_QG75dpfcHvpKXu2SO8fjiflD8vtL1y5TlL-0ac8aGyO0aBfowmMs9arp6SG9bC7WPQUoeep_jZGxLbVX1NCfQzUKeo6Be_DQDUG7pAiY-E8JNSC9utSMrPYOZ4Tbl_FI4BE5Ofr448MiHfsupDVYU6uUh8CLIEB9KuxrZW0JOt7K0gvhhKmlqllllJE-M465UKNX6bzjZVaZ2gmRPyY7bdf6p4QykXkweErLOcPzZgUOjMwNy0ImQ-5MQt5NbNDjB-noliipB6ZpYJqOTNNFQg6RUxtKLI0dbwBg9AgY_S_AJOQ18llj8YsWo2uWZt33-tP3b_pAcZBfsuIyIW9HotDBOtZmTFaAr8J6WTPKvRkl7M56NvxqgpPGIQxpa3237jV2DEMDNCu30PDo8xX5tnk4kzzDBOaEPBlgulkgsD4lFyVPiJoBeLaC85G2OYtFxoEFOchzmPT9hHU9ird-C4ue_Q8WPSd3-bBX06zcIzuri7V_Abbfyr6M2_wPUONVAA priority: 102 providerName: Directory of Open Access Journals |
| Title | Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector |
| URI | https://link.springer.com/article/10.1186/s12985-025-02662-5 https://www.ncbi.nlm.nih.gov/pubmed/39962472 https://www.proquest.com/docview/3168025017 https://www.proquest.com/docview/3200255536 https://www.proquest.com/docview/3206214069 https://pubmed.ncbi.nlm.nih.gov/PMC11834259 https://doaj.org/article/0d7616d8542241dab6d8ae484187bb37 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9MwFLfYJtAuCMZXYFQGIXGAiMRxbOfYVptKxSa0Mak3y4mdrgeSaWknduUv5z0nrZaBKnGoWsWvjuLf8_vI-zAhH0RkBOhdG_IylyF3tgizUqVhZtMycg6YSGFx8smpmFzw6SyddW1ysBbmbvw-VuJLA_pIYQ0xfoQAx2mH7KUgeJGbx2K8lrpghchsXRTzz__1FI_vz_-3FL6jhu6nSN6Lk3r1c_yEPO7sRjpsgX5KHrjqgDxsT5K8PSCPTroY-TPy-1tdzUOUuHRRXS5yn5NF65JOHGZPLxcNHdGbxfWqocA8jrpfXS5sRfNbauhV23-C_sRUPbjphqCaU2QR_26EGpBXdWg6cJ3FGeHyjQ8CPCcXx0c_xpOwO2khLMB-WoasLFlaclCYCk-yynMJWj0X0nFuuSmEKqLMKCNcbGxkywL9SOssk3FmCst58oLsVnXlXhEa8diBiSNzxiKMMCtwWURioriMRZlYE5BPaxh090DaOyJK6BY0DaBpD5pOAzJCpDaU2AzbXwAe0d3e0pGVIhZWpRztEWty-G0cVzxWMs8TGZD3iLPGdhcV5tPMzapp9NfzMz1UDCSWyJgIyMeOqKxhHQvTlSfAU2GHrB7lYY8S9mPRG363ZieNQ5jEVrl61Wg8IwxNzlhuoWHey0uTbfOwSLAYS5YD8rJl080Cgb0pGJcsIKrHwL0V7I9Ui0vfVhwgSECCw6Sf17yuO4HWbIHo9f-RvyH7rN2VYSwPye7yeuXegl23zAdkR87kgOwNh9PzKXyPjk6_nw38Nh_4dyV_AOcVSw8 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9MwFLdgCMYFwfgKDDAIiQNEJI5jO8etYuqg3QE2aTfLju2uhyVoaSd25S_nvSStloEqcYhUxS-O4t_z--j7MCHvRWIE6F0X82BlzL0r4yKoPC5cHhLvgYkUFidPj8T4hH89zU_7NjlYC3M9fp8q8bkBfaSwhhgvIcBxuk3uYOQS--SPxGgldcEKkcWqKOafzw0UT9uf_28pfE0N3UyRvBEnbdXPwUPyoLcb6V4H9CNyy1c75G53kuTVDrk37WPkj8nvSV3NYpS4dF6dzW2bk0XrQMces6cX84bu08v5xbKhwDye-l99LmxF7RU19GfXf4KeY6oevHRNUM0oskj73wg1IK_q2PTgeoczwu3LNgjwhJwcfDkejeP-pIW4BPtpEbMQWB44KEyFJ1lZK0GrWyE9546bUqgyKYwywqfGJS6U6Ec675hMC1M6zrOnZKuqK_-c0ISnHkwcaRlLECcFLovITJKGVITMmYh8XMGg-w_SrSOihO5A0wCabkHTeUT2Eak1JTbDbm8Aj-h-b-nESZEKp3KO9ogzFn4bzxVPlbQ2kxF5hzhrbHdRYT7NzCybRh_--K73FAOJJQomIvKhJwo1rGNp-vIE-CrskDWg3B1Qwn4sB8NvV-ykcQiT2CpfLxuNZ4ShyZnKDTSs9fLybNM8LBEsxZLliDzr2HS9QGBvCsYli4gaMPBgBYcj1fysbSsOEGQgwWHSTyte171AazZA9OL_yN-Q7fHxdKInh0ffXpL7rNuhcSp3ydbiYulfgY23sK_bzf0HdCNI_A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1Nb9Mw1IJNTFwQDBiBAQYhcYBoiePYzrEDpq5sE2JM2s1yYrvrgWRq2old-eW8l49qGagSh0hR_OLIft95HybknYiMAL1rQ-5zGXJnizDzKg0zm_rIOSAihcXJxydifMYn5-n5jSr-Jtu9D0m2NQ3Ypalc7F1a37K4Ens1aCmFlcV4CQHu1F2yqdIsA_drczSanE56aQzWicz6Ypl_vjlQSE3f_r-l8w31dDt18lb8tFFLBw_Jg86epKOWAB6RO67cJvfaEyavt8nWcRc7f0x-H1XlNERJTGflxSxvcrVo5enYYVb1YlbTfXo1my9rCkTlqPvV5ciWNL-mhl62fSnoT0zhg4-uAMopRdJp_plQA3KsCk2HdGdxRnh81QQHnpCzgy8_Po3D7gSGsAC7ahEy71nqOShShSdc5bkEbZ8L6Ti33BRCFVFmlBEuNjayvkD_0jrLZJyZwnKePCUbZVW6Z4RGPHZg-sicsQgjzwpcGZGYKPax8Ik1AfnQo0F3C9KNg6KEbpGmAWm6QZpOA7KPmFpBYpPs5kE1n-qO53RkpYiFVSlHO8WaHO6N44rHSuZ5IgPyFvGssQ1GiXk2U7Osa314-l2PFANJJjImAvK-A_IV7GNhurIFWBV2zhpA7g4ggU-LwfCbnpw0DmFyW-mqZa3x7DA0RWO5BoY13l-arJuHRYLFWMockJ2WTFcbBHaoYFyygKgBAQ92cDhSzi6aduOAggQkO0z6sad13Qm6eg2Knv8f-Guy9e3zgT46PPn6gtxnLYOGsdwlG4v50r0E02-Rv-q4-w_M61K6 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+inhibition+of+Hepatitis+B+virus+gene+expression+by+a+primary+microrna+expressing+ancestral+adeno-associated+viral+vector&rft.jtitle=Virology+journal&rft.au=Mnyandu%2C+Njabulo+Ziphezinhle&rft.au=Limani%2C+Shonisani+Wendy&rft.au=Ely%2C+Abdullah&rft.au=Wadee%2C+Reubina&rft.date=2025-02-17&rft.issn=1743-422X&rft.eissn=1743-422X&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12985-025-02662-5&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12985_025_02662_5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-422X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-422X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-422X&client=summon |